In some cases, it can be a symptomatic treatment in that it may be used to improve a patient’s symptoms, when other treatments fail, even if for some reason the symptomatic improvement does not persist after the T3 therapy has been discontinued.

In some cases, it can be a therapeutic treatment in the sense that the symptoms remain improved even after the treatment has been discontinued.

It can also be used as a prophylactic treatment in that some patients have noticed that small doses of T3 can be used to ward off relapses of Wilson’s Temperature Syndrome. Some patients (especially those with hereditary predispositions to Wilson’s Temperature Syndrome) have learned to predict when their symptoms are likely to relapse. Upcoming conditions of emotional stress can cause relapses in patients who are remaining well after the T3 therapy has been discontinued. For example, one susceptible patient was required to give an important presentation every 3 months. She noticed her symptoms relapsing after her first “post-T3″ presentation. She was able to quickly nip her symptoms “in the bud,” by starting back up on a small cycle of T3 therapy once her symptoms reappeared. She found she was able to predict a relapse with almost every quarterly presentation she was required to make. She also found that she was able to ward off relapses by taking the lowest dose of 7.5 mcg p.o. BID (lower doses can be made for more sensitive patients, but it is rarely necessary) the day before, the day of, and the day after her presentations. And thus she was able to see her presentations come and go without the first onset of symptoms. Likewise, some such patients feel more comfortable just staying on the lowest dose of T3 therapy as maintenance to more continually exert the slightest pressure against a relapse, but such cases are exceptional.